LicianPro

Metagenomi Therapeutics, Inc. ·

MGX 8-K 2026-09-22

Metagenomi Therapeutics, Inc. (MGX) 8-K dated 2026-09-22 — accession 0001193125-26-397037.

Metagenomi Therapeutics, Inc. (MGX) is a biotechnology company listed on NASDAQ.

Metagenomi Therapeutics, Inc. filed a 8-K on 2026-09-22. Accession 0001193125-26-397037.

This 8-K covers: Reg FD disclosure (Item 7.01), Exhibits (Item 9.01). SEC EDGAR holds the official filing and its exhibits.

Latest reported MGX revenue for 2025-12-31 was $25.2M. Net income was -$87.9M. Revenue was down 51.8% from 2024-12-31 to 2025-12-31. MGX currently screens at market cap $44.4M.

Not investment advice. The MGX SEC hub lists recent forms. The stock page is the research view.

Open on SEC EDGAR

These filings as JSON? API free 100/day

Lician Pro $19.99/mo or $149/yr